Month: November 2020

Register for our upcoming “Ask Us Anything In Clinical Research – Medical Device and Diagnostic Studies” virtual networking meeting!

11/03/2020

We are absolutely delighted with the positive engagement we’ve had from our first four Ask Us Anything in Clinical Research – Virtual Networking Meetings. It’s hard to believe we have had this many so far! Based on this success, we have decided to continue the series into 2021 with our next virtual meeting on November…

Read More

How scientists launched a study in days to probe COVID-19’s unpredictability

11/03/2020

Excerpt from the Article: On a Friday afternoon in mid-March 2020, as the emergency department at Massachusetts General Hospital began admitting its first coronavirus patients, attending emergency physician and researcher Michael Filbin recognized an urgent need to quickly learn about the emerging pathogen. With a surge of COVID-19 patients expected in the hospital in the…

Read More

IM Therapeutics Launches Phase 1b Trial of Lead Drug IMT-002 in Autoimmunity; Announces Positive Safety Data of Phase 1a Study

11/02/2020

Excerpt from the Press Release: WOBURN, Mass.–(BUSINESS WIRE)–ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a leading innovator in the field of precision medicine for autoimmune diseases, today announced it has launched a Phase 1b study as a multiple ascending dose (MAD) trial. The study is in patients who have type 1 diabetes (T1D), an as yet incurable…

Read More

REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements

11/01/2020

Excerpt from the Article: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. Specifically, based on a potential safety signal and an unfavorable risk/benefit profile at this time, the IDMC recommends further…

Read More